



# Recombinant Human Claudin-18.2 (N-8His)

<b>Catalog #</b>	EPT068
<b>Expression Host</b>	E.coli
<b>DESCRIPTION</b>	Recombinant Human CLDN18.2 is produced by our E.coli expression system and the target gene encoding Asp28-Leu76 is expressed with a 8His tag at the N-terminus.
<b>Accession</b>	P56856-2
<b>Synonyms</b>	Claudin-18; CLDN18
<b>Mol Mass</b>	19.7 KDa
<b>AP Mol Mass</b>	18 KDa, reducing conditions
<b>Purity</b>	Greater than 95% as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	Less than 0.1 ng/μg (1 EU/μg) as determined by LAL test.
<b>FORMULATION</b>	Supplied as a 0.2 μ m filtered solution of 25mM Tris-HCl, 25mM NaCl, 0.1% Triton X-100, 10% glycerol, pH 8.0.





## RECONSTITUTION

## SHIPPING

The product is shipped on dry ice/polar packs.

Upon receipt, store it immediately at the temperature listed below.

## STORAGE

Store at  $\leq -70^{\circ}\text{C}$ , stable for 6 months after receipt.

Store at  $\leq -70^{\circ}\text{C}$ , stable for 3 months under sterile conditions after opening.

Please minimize freeze-thaw cycles.

## BACKGROUND

Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas






**ELK Biotechnology**

and pancreatic tumors. IMAB362 was developed by  
Ganymed Pharmaceuticals AG.

## SDS-PAGE



+86-27-59760950

ELKbio@ELKbiotech.com

www.elkbiotech.com

23-2, No.388 Gaoxin 2nd Road, Wuhan East Lake Hi-tech Development Zone, Hubei, P.R.C